PT - JOURNAL ARTICLE AU - Yang, Wan AU - Shaman, Jeffrey TI - SARS-CoV-2 transmission dynamics in South Africa and epidemiological characteristics of the Omicron variant AID - 10.1101/2021.12.19.21268073 DP - 2021 Jan 01 TA - medRxiv PG - 2021.12.19.21268073 4099 - http://medrxiv.org/content/early/2021/12/21/2021.12.19.21268073.short 4100 - http://medrxiv.org/content/early/2021/12/21/2021.12.19.21268073.full AB - Within days of first detection, Omicron SARS-CoV-2 variant case numbers grew exponentially and spread globally. To better understand variant epidemiological characteristics, we utilize a model-inference system to reconstruct SARS-CoV-2 transmission dynamics in South Africa and decompose novel variant transmissibility and immune erosion. Accounting for under-detection of infection, infection seasonality, nonpharmaceutical interventions, and vaccination, we estimate that the majority of South Africans had been infected by SARS-CoV-2 before the Omicron wave. Based on findings for Gauteng province, Omicron is estimated 100.3% (95% CI: 74.8 - 140.4%) more transmissible than the ancestral SARS-CoV-2 and 36.5% (95% CI: 20.9 - 60.1%) more transmissible than Delta; in addition, Omicron erodes 63.7% (95% CI: 52.9 - 73.9%) of the population immunity, accumulated from prior infections and vaccination, in Gauteng.Competing Interest StatementJS and Columbia University disclose partial ownership of SK Analytics. JS discloses consulting for BNI.Funding StatementThis study was supported by the National Institute of Allergy and Infectious Diseases (AI145883 and AI163023), the Centers for Disease Control and Prevention (CK000592), and a gift from the Morris-Singer Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in this study are publicly available as described in the “Data sources and processing” section.